Delivery Order SPE2DB22D1202-SPE2DB25FVMA4
- Not listed
- The Defense Logistics Agency awarded a $3,274.31 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60 ml), a pharmaceutical product used in treating attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $2,957.94 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (120 mL) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed price delivery order was issued on a non-set-aside basis and represents a pediatric ADHD medication supply under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,464.90 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL), a medication commonly used to treat attention deficit hyperactivity disorder. This firm fixed-price delivery order, awarded on August 6, 2025, is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through...
- The Defense Logistics Agency awarded a delivery order valued at $2,050.33 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL) on August 22, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,764.78 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml), a medication commonly used to treat attention deficit hyperactivity disorder. This firm fixed-price delivery order, awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a non-competitive set-aside award. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,334.63 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), with a completion date of May 28, 2025. This is a firm fixed price, non-set-aside delivery order issued under a competitive award process. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military...
- The Defense Logistics Agency awarded a $1,314.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60ml), with an ultimate completion date of August 1, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a competitive delivery order valued at $1,971.30 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. The award, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, represents a firm fixed price transaction with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $1,546.42 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), with a firm fixed price and ultimate completion date of September 22, 2025. This is a non-set-aside, competitively awarded delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a $2,230.34 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60 ml), a pharmaceutical product used to treat attention-deficit/hyperactivity disorder. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order with an ultimate completion date of September 9, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVMA4Delivery Order
The Defense Logistics Agency awarded a $2,891.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), with an ultimate completion date of September 23, 2025. This non-set-aside contract represents a pediatric ADHD medication supply supporting federal healthcare operations. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs, including specialty medications, brand-name and generic drugs, and vaccines. The delivery order fulfills immediate pharmaceutical requirements for federal medical procurement while operating within the broader framework of this extensive pharmaceutical prime vendor agreement supporting the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 9/22/25 |